SecBot SecBot
8-K ·Filed Aug 10, 2026

FULC

Fulcrum Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001193125-26-341385
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

No trading signal from this routine officer role consolidation. Monitor next 10-Q for any material weakness or control change disclosure, but none is expected from this internal move.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$3.75
T+0 close · Aug 10, 2026 · via day close
Latest settled
−0.27%
T+60 · $3.74
Vs SPY
+2.15%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 10 $3.75entry
  2. T+1 · 3mo ago −1.60%α −1.28% · $3.69
  3. T+5 · 3mo ago +2.40%α +2.45% · $3.84
  4. T+20 · 2mo ago +1.87%α +2.78% · $3.82
  5. T+60 · 14d ago −0.27%α +2.15% · $3.74
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Fulcrum Therapeutics VP of Finance and principal accounting officer Greg Tourangeau mutually agreed to depart, effective August 7, 2026. CFO Alan Musso has been appointed as the new principal accounting officer, effective the same date, receiving no additional compensation. This is a routine internal realignment of accounting officer duties with no financial impact.

Key Facts

  • Greg Tourangeau departed as VP of Finance and principal accounting officer on August 7, 2026, per a mutual agreement first disclosed on June 11, 2026.
  • Alan Musso, the company's CFO and principal financial officer, was appointed principal accounting officer effective August 7, 2026.
  • Musso will receive no additional compensation for the additional role.

Financial Impact

No financial impact, internal reassignment of accounting officer duties with no compensation change.

Risk Factors

  • No material risks identified from this routine internal reassignment.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-341385
Document: 0001193125-26-341385-index-headers.html0001193125-26-341385
Document: 0001193125-26-341385-index.html0001193125-26-341385
Document: 0001193125-26-341385.txt0001193125-26-341385

Track record

23 reports on FULC

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
  3. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  4. Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
  5. Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  6. Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
  7. Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
  8. Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
  9. Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
  10. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026